PCDHB4 as A Potential Drug Target and Biomarker for Diseases (G56131)

Target Name: PCDHB4

NCBI ID: G56131

PCDHB4

PCDHB4 as A Potential Drug Target and Biomarker for Diseases

PCDHB4 (Peripheral Component Data Handle 4) is a non-coding RNA molecule that is expressed in various tissues throughout the body. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer. In this article, we will discuss PCDHB4 as a potential drug target and its potential as a biomarker for several diseases.

PCDHB4 functions as a negative regulator of the TGF-β signaling pathway. The TGF-β pathway is a well-established regulator of cell proliferation and is involved in the development and maintenance of tissues and organs. PCDHB4 is expressed in various tissues, including fetal brain, placenta, and breast tissue, and has been shown to regulate the expression of TGF-β target genes.

PCDHB4 has been shown to play a role in the development and progression of several diseases, including cancer. For example, studies have shown that PCDHB4 is downregulated in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, PCDHB4 has been shown to be involved in the regulation of cell apoptosis, which is a natural process that helps the body remove damaged or dysfunctional cells.

PCDHB4 has also been shown to be a potential biomarker for several diseases, including cancer. For example, studies have shown that PCDHB4 can be used as a biomarker for breast cancer, with higher expression levels of PCDHB4 in breast tissue samples from patients with breast cancer. Additionally, PCDHB4 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer, making it a potential biomarker for these diseases.

PCDHB4 has also been shown to have potential therapeutic applications. For example, studies have shown that PCDHB4 can be downregulated using small molecules, such as inhibitors, which can lead to the inhibition of TGF-β signaling and the regression of cancerous tumors. Additionally, researchers have shown that PCDHB4 can be overexpressed in cancer cells using RNA interference technology, which can lead to the inhibition of TGF-β signaling and the regression of cancerous tumors.

In conclusion, PCDHB4 is a non-coding RNA molecule that is expressed in various tissues throughout the body and is involved in the regulation of cell proliferation and apoptosis. Its functions as a negative regulator of the TGF-β signaling pathway and as a potential biomarker for several diseases make it a promising target for therapeutic applications. Further research is needed to fully understand the role of PCDHB4 in diseases and to develop safe and effective therapies based on PCDHB4.

Protein Name: Protocadherin Beta 4

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets